Numab Therapeutics
PrivateLast Round
Series C
Extension
Jan 9, 2025
Est. Valuation
$1.25B
Total Funding Raised
$187.6M
Company Overview
Numab Therapeutics operates in Healthcare & Life Sciences and is based in Horgen. Its latest recorded funding round was a Series C Extension round in January 2025.
Numab Therapeutics is a biotechnology company that develops multispecific antibody-based immunotherapies for the treatment of chronic inflammation and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Numab Therapeutics Comparables
Compare Numab Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Crescendo Biologics Ltd. | 84% | |
| EpimAb Biotherapeutics | 83% | |
| Adimab | 82% |
For institutional investors. Book with your work email.
Numab Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jan 9, 2025 | ||||
| M&A | Jul 11, 2024 | ||||
| Series C | May 20, 2021 | ||||
| Series B | Mar 9, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Numab Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series C Extension |
| Octagon Capital Advisors | Series C Extension, Series C |
| Cormorant Asset Management | Series C, Series C Extension |
| Flerie Invest | Series C Extension, Series C |
| HBM Healthcare Investments | Series C Extension |
| Novo Holdings | Series C Extension, Series C |
| BVF Partners L.P. | Series C Extension, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 121% MoM, reaching 4.1K.
- Sep 25, 2025
Achieved an unspecified milestone in collaboration with Boehringer Ingelheim.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 1, 2026
In Switzerland on Oct 1st '26, Numab appointed Dr. Rajesh Chopra as Chief Scientific Officer to advance its proprietary multispecific antibody pipeline.
For institutional investors. Book with your work email.
Numab Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Numab Therapeutics's valuation, stock price, and market status.
Is Numab Therapeutics a public or private company?
Numab Therapeutics is a private company.
What is the current stock price of Numab Therapeutics?
Numab Therapeutics is a private company, so its shares have no public market price. Caplight tracks Numab Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Numab Therapeutics worth (valuation)?
Numab Therapeutics's valuation is estimated at $1.3B based on funding round data.
Can I buy Numab Therapeutics stock?
Numab Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Numab Therapeutics's last funding round?
Numab Therapeutics's most recent funding round was Series C Extension on January 9, 2025.
Who are the main investors in Numab Therapeutics?
Key investors in Numab Therapeutics include Forbion, Cormorant Asset Management, Novo Holdings, Cormorant Asset Management, HBM Partners.
Will Numab Therapeutics IPO soon?
No public IPO plans have been announced for Numab Therapeutics.
How can I track Numab Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Numab Therapeutics's shares on secondary markets.